Background: Breast cancer survival has been shown to be associated among relatives. In this study, we used a population-based cohort of Swedish sisters, both diagnosed with breast cancer, to determine whether prognostic information of a previously diagnosed sibling is useful for the clinical management of a newly diagnosed sibling.
introduction
Standard prognostic breast cancer markers include estrogen receptor (ER) status, progesterone receptor (PR) status and human epidermal growth factor receptor 2 (HER2), together with tumor size, histological grade and lymph node status. Despite achievements in the use of adjuvant therapies, one of five women with early-stage breast cancer will later develop distant metastatic disease [1] [2] [3] [4] , which is the cause for virtually all breast cancer death. It has been proposed that genetic background of a cancer patient may be essential for the metastatic ability of the tumor [5] .
Through large population-based register studies, we have shown that survival from breast cancer is associated among relatives, consistent with an inherited cancer [6] [7] [8] [9] . One potential explanation for the inheritance of survival could be that family members are predisposed to developing a breast cancer tumor of predefined biology. This is plausible, given the observation that carriers of mutations in high-risk and moderate-risk genes are often predisposed to specific subtypes of breast cancer [10] [11] [12] [13] [14] [15] . In addition, genetic variants associated with breast cancer tumor characteristics such as ER status have recently been identified in large genome-wide association studies [12] [13] [14] . An alternative hypothesis is that antitumoral immune response and/or response to systemic treatment is inherited [16] [17] [18] . Shared characteristics, such as health-seeking behavior, treatment choices and lifestyle may also play a role in the correlation of survival among the relatives [19, 20] .
In this study, we determined whether basic prognostic information of a previously diagnosed sister, as likely known by the newly diagnosed sister, could be used in the clinical management of breast cancer as an independent prognosticator. In addition, we tested whether sisters were associated by tumor characteristics since it could be one potential explanation for the inheritance of prognosis. Our analyses are based on a large population-based cohort including all sister pairs diagnosed with breast cancer in Sweden between 1992 and 2006.
patients and methods

Swedish population-based sister cohort
In Sweden, all residents have a unique national registration number, which makes linkage of different records of personal information possible. Our population-based cohort of sisters diagnosed with breast cancer was defined by a record linkage between several population-based registers namely the MultiGeneration Register, the Swedish Cancer Register, the Cause of Death Register and the Migration Register. Additional linkages were also made to the censuses of 1960, 1970, 1980 and 1990 , which contain information on individual socioeconomic status. Cancer registration has a legal basis in Sweden, and the Swedish Cancer Registry has a breast cancer coverage of >96% in validation studies [21] .
The Swedish population-based Sister cohort included all sister pairs diagnosed with breast cancer from 1 January 1992 through 31 December 2006, in total 1617 sisters (834 sister pairs including 17 families with 3 sisters) with complete follow-up until 31 December 2010. All clinical information was collected from original pathology reports and medical records by one research nurse specialized in breast cancer, resulting in the comprehensive material forming the basis of this study.
The Swedish National Cause-of-Death Register was founded in 1961 and has a reported accuracy of 96% from 1 January 1961, onwards [22, 23] . Information on cause of death is ascertained from death certificates filled in by treating physicians. The register includes date of death, underlying and contributory causes of death, in addition to, information on autopsies, histological verification of disease and other information. It should be underlined that the Register includes all underlying causes of death.
The study was approved by the ethics committee at Karolinska Institutet. For simplicity, we refer to these categories as good, expected and poor. Thereafter, the survival in the younger sister in relation to the older sister survival was assessed. First, we carried out adjusted Kaplan-Meier [25] analyses of younger sister breast cancer-specific survival according to older sister survival. The older sister survival was categorized according to either good survival or poor survival (expected and poor survival combined). The adjusted Kaplan-Meier analysis was adjusted for the variables as included in the fully adjusted model (as described below).
Second, the younger sister survival was modeled with a multivariate proportional hazard (Cox) analysis according to older sister survival. In the partly adjusted multivariate model, younger sister survival was adjusted for age and calendar period of diagnosis, socioeconomic factors, number of children and hospital of primary tumor diagnosis. In the fully adjusted multivariate model younger sister survival was additionally adjusted for tumor characteristics namely tumor grade, tumor stage, presence of cancer in situ component within the invasive cancer, ER status, PR status, adjuvant hormonal therapy and chemotherapy.
The younger sisters were followed for up to 5 years after breast cancer diagnosis and older sisters for up to 10 years after diagnosis (to have as complete an exposure assessment as possible). An arbitrary level of 5% statistical significance (two-tailed) was used. The proportional hazard assumption for the main exposure variable was assessed including a time dependent covariate in the model. No significant deviation was noted (P = 0.35). All data preparation and analysis was done using SAS version 9.3.
results
The Swedish population-based cohort included all sisters diagnosed with breast cancer from 1 January 1992 through 31 December 2006, with detailed clinical information and complete follow-up (31 December 2010), in total 1617 sisters. All patient information was collected manually from original pathology reports and patient records. A descriptive summary of the sister cohort, including information on common breast cancer risk factors, primary tumor characteristics and adjuvant therapy, stratified by birth order (younger or older sister) is given in Table 1 .
The kappa statistic was used to measure the association of tumor characteristics between the sisters. Only ER status was significantly associated between the tumors of the sisters {κ 0.18 [95% confidence interval (CI) 0.089-0.27]; Table 2} . No significant association was found for tumor size or tumor stage. Kappa statistic for tumor size was even found to be non-significantly negative [κ −0.022 (95% CI −0.084-0.041)]. If anything, our findings (negative κ value for tumor size, however nonsignificant) suggest the opposite; a younger sister of breast cancer patient diagnosed with aggressive breast disease might seek care earlier. Mode of detection, screening detected versus nonscreening detected breast cancer, did not differ between the sisters (Table 2) .
Using an adjusted Kaplan-Meier method, younger sisters with poor older sister survival showed significantly worse survival compared with patients with good older sister survival ( Figure 1 , P = 0.0172). Further, using a multivariate proportional hazard (Cox) analysis adjusted for age and calendar period of diagnosis, socioeconomic factors, number of children and hospital of primary tumor diagnosis (partly adjusted model), a more than twofold increased hazard ratio (HR), i.e. risk for death from breast cancer was found in younger sisters with poor older sister survival (10- 
discussion
Our findings suggest that basic prognostic information of a sister previously diagnosed with breast cancer could be useful in the clinical management of breast cancer as an independent prognosticator for a newly diagnosed sister. In the populationbased cohort, sisters were significantly but only slightly associated with regards to ER status. The risk of death from breast cancer in sisters whose older sister had a poor survival was more than threefold greater compared with patients with a good sister survival, after adjusting for patient and tumor characteristics, and type of adjuvant therapy.
Our large population-based study has several strengths, importantly we included all sister pairs diagnosed with breast cancer in Sweden between 1992 and 2006 through an unbiased assessment of family history since information on cancers in relatives was retrieved from the Multi-Generation Register and Swedish Cancer Register and not retrieved from case records. Through the Cause of Death Register we have a complete ascertainment and follow-up of patients with breast cancer. In addition, the medical history was manually collected from original pathology reports and patient records by an experienced research nurse specialized in breast cancer. We abstracted detailed information on medical history, tumor characteristics, as well as information on treatment together with available data of epidemiological nature and other relevant information as collected by the Swedish health care system. One important concern in our study is the latency period, defined as the period of time between when a tumor is possible to detect and the date of diagnosis. The latency period is possibly affected by awareness, denial, socioeconomic status and access to health care. Still, Sweden has a tax-funded health care system available to everyone at minimal cost making major differences between patients unlikely. Importantly, in our analyses, we do not see a correlation between sisters in tumor size or tumor stage indicating that awareness, denial, etc., is not affecting our results. If anything, our findings (negative κ value for tumor size, however nonsignificant) suggest the opposite, younger sisters that lost a sister to breast cancer might seek care earlier. Such findings have also been seen in previous Swedish [20, 26] . Similar behavior in the nationwide Swedish mammographic screening program could possibly contribute to survival correlation within families. However, we do not see an association in mode of detection between the sisters. In addition, the mortality difference observed between families was substantially larger than the documented benefit from regular mammography screening [23] . Due to the lack of information on obesity and overweight, lifestyle and diet, we could not assess the effect of familial clustering of such factors with breast cancer survival [27] . Even though we have treated socioeconomic status as a crude proxy [19, 20] , it is still unlikely that this measure will be adequate to control for all social and lifestyle factors, hence the possibility of residual confounding persists. The same can be said for the dichotomization of treatment variables. Our results suggest that familial clustering of breast cancer survival is mainly determined biologically, rather than a consequence of confounding by health-seeking behavior, social class and lifestyle. However, it should be noted that social and lifestyle factors are more difficult to assess and the associated measurements are harder to characterize and quantify than biological factors, which can diminish their influence. The genetic background of an individual has been suggested to influence tumor characteristics as well as disease progression and survival. Carriers of mutations in high-risk and moderaterisk genes are often predisposed to specific ER subtypes of breast cancer, and common variants identified through genome-wide association studies tend to also be associated with ER-specific subtypes. Some variants are more strongly associated with ER negative or triple negative (ER-negative, PRnegative and HER2-negative) breast cancer [10, 11, 28] , whereas others are more strongly associated with ER-positive breast cancer [12] [13] [14] . In the current study, ER status was significantly associated in sisters in contrast to tumor size, grade, stage, morphology, proliferation and lymph node status, where no significant association was found.
Inheritance of host characteristics is a possible explanation for the inherited prognosis since several studies have shown individual differences in the ability to tolerate and/or respond to systemic treatment. Indeed, differences in the ability to respond to hormonal therapy have previously been related to a genetic variation in CYP2D6/2C19 [29] . Genetic variation in oxidative stress (OS)-related genes [30] has been suggested to influence response to adjuvant chemotherapy. Host toxicity to chemotherapy has also been associated with genetic variability [31] [32] [33] . Furthermore, immunologic response has been proposed to enhance the effects of systemic therapy [16] . Several studies have shown presence of lymphocytic infiltration in breast cancer tumors to be associated with improved outcome in patients [17, 18] . In addition, we recently identified a single nucleotide polymorphism near the CCL20 gene (2q36.3) implicated in immune response to be associated with breast cancer survival independent of known prognosticators [34] . This suggests that host factors affecting the ability to mount an effective immunological response might indeed contribute to the inheritance of breast cancer prognosis. Figure 1 . Kaplan-Meier survival curves of younger sisters by older sister survival. The 10-year cause-specific breast cancer survival in the older sisters was modeled by multivariate proportional hazard analysis (adjusting for calendar year and age at diagnosis) and the residuals from this model were categorized according to tertiles of survival to define a poor as well as a good older sister survival group. Younger sister cause-specific survival was modeled from the time of primary breast cancer diagnosis to death or censoring contrasting good and poor older sister survival. 
